Hikma Pharmaceuticals (LON:HIK) Rating Reiterated by Berenberg Bank

Hikma Pharmaceuticals (LON:HIK - Get Free Report)'s stock had its "hold" rating reaffirmed by analysts at Berenberg Bank in a research note issued on Thursday, MarketBeat.com reports. They presently have a GBX 2,000 ($24.70) target price on the stock. Berenberg Bank's target price indicates a potential upside of 4.55% from the company's previous close.

Separately, Barclays reissued an "equal weight" rating and issued a GBX 2,000 ($24.70) price target on shares of Hikma Pharmaceuticals in a research report on Monday, April 8th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of GBX 2,068.75 ($25.55).

Hikma Pharmaceuticals Stock Up 3.2 %

LON HIK traded up GBX 59 ($0.73) on Thursday, reaching GBX 1,913 ($23.63). The company had a trading volume of 366,712 shares, compared to its average volume of 426,113. The stock has a market capitalization of £4.24 billion, a P/E ratio of 2,855.22, a P/E/G ratio of 2.38 and a beta of 0.45. The company's fifty day moving average is GBX 1,887.50 and its 200 day moving average is GBX 1,870.12. Hikma Pharmaceuticals has a 52-week low of GBX 1,711 ($21.13) and a 52-week high of GBX 2,222 ($27.45). The company has a quick ratio of 1.27, a current ratio of 1.57 and a debt-to-equity ratio of 53.92.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.